Dotter Inc. acquired the exclusive domestic rights to EluNIR™ through a recent contract with Israeli company Medinol.
EluNIR™ is a Ridaforolimus drug-releasing stent that prevents tissue prolapse by continuously supporting the blood vessel wall by increasing the ability to maintain cell size in curved lesions with WiZeCell (W-Z strut design) technology.
In addition, the ultra-narrow “Z” strut with a width of 40μm has fewer blood vessel wall footprints generated from metal stents This makes it easy to recover as there is less trauma to the vessel wall that may occur during the procedure. EluNIR™ is scheduled to be marketed in Korea early next year through Dotter.
EluNIR™ is a Ridaforolimus drug-releasing stent that prevents tissue prolapse by continuously supporting the blood vessel wall by increasing the ability to maintain cell size in curved lesions with WiZeCell (W-Z strut design) technology.
In addition, the ultra-narrow “Z” strut with a width of 40μm has fewer blood vessel wall footprints generated from metal stents This makes it easy to recover as there is less trauma to the vessel wall that may occur during the procedure. EluNIR™ is scheduled to be marketed in Korea early next year through Dotter.
